StockData
Johnson & Johnson logo

Johnson & Johnson (JNJ) operating KPIs

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)

Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%

Johnson & Johnson cOVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide sales ($M) ($M)

Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule

Latest, FY2024
198
Period ended Dec 29, 2024
Change on a year earlier
-82.3%
1,117 in FY2023
History
6 years
Since FY2019
Sources
4
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCOVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide sales ($M) ($M)Year on yearSource
FY2024Dec 29, 2024198-82.3%Form 10-K (filed 2025-02-13) ↗
FY2023Dec 31, 20231,117-48.7%Form 10-K (filed 2025-02-13) ↗
FY2022Jan 1, 20232,179-8.6%Form 10-K (filed 2025-02-13) ↗
FY2021Jan 2, 20222,385–Form 10-K (filed 2024-02-16) ↗
FY2020Jan 3, 20210–Form 10-K (filed 2023-02-16) ↗
FY2019Dec 29, 20190–Form 10-K (filed 2022-02-17) ↗

Breakdown

What makes up covid-19 vaccine (ad26.cov2.s) [reported through fy2024q4] — worldwide sales ($m)

Cite this data

StockData. (2026). Johnson & Johnson COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide sales ($M) ($M), annual FY2019–FY2024 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_covid19

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.